ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
ImmunoPrecise Antibodies Ltd

ImmunoPrecise Antibodies Ltd (IPA)

1.18
0.06
(5.36%)
Closed May 19 4:00PM
1.10
-0.08
(-6.78%)
After Hours: 6:26PM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
1.10
Bid
1.11
Ask
1.24
Volume
183,358
1.07 Day's Range 1.27
0.94 52 Week Range 3.39
Market Cap
Previous Close
1.12
Open
1.13
Last Trade Time
Financial Volume
$ 215,188
VWAP
1.1736
Average Volume (3m)
612,377
Shares Outstanding
25,050,260
Dividend Yield
-
PE Ratio
-1.11
Earnings Per Share (EPS)
-1.06
Revenue
20.67M
Net Profit
-26.56M

About ImmunoPrecise Antibodies Ltd

ImmunoPrecise Antibodies Ltd is a supplier of custom antibodies to the research industry and industrial community. The company has aggregated its operations into one reportable segment, Antibody Production, and Related Services. It operates in three principal geographical areas - the United States o... ImmunoPrecise Antibodies Ltd is a supplier of custom antibodies to the research industry and industrial community. The company has aggregated its operations into one reportable segment, Antibody Production, and Related Services. It operates in three principal geographical areas - the United States of America, Canada, Europe, and others. The majority of its revenue is derived from the United States of America. Show more

Sector
Pharmaceutical Preparations
Industry
Miscellaneous Metal Ores,nec
Headquarters
Victoria, British Columbia, Can
Founded
2016
ImmunoPrecise Antibodies Ltd is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker IPA. The last closing price for ImmunoPrecise Antibodies was $1.12. Over the last year, ImmunoPrecise Antibodies shares have traded in a share price range of $ 0.94 to $ 3.39.

ImmunoPrecise Antibodies currently has 25,050,260 shares outstanding. The market capitalization of ImmunoPrecise Antibodies is $29.56 million. ImmunoPrecise Antibodies has a price to earnings ratio (PE ratio) of -1.11.

IPA Latest News

InterSystems et BioStrand, filiale d’IPA, collaborent au lancement de l’intégration innovante de la recherche vectorielle et de LENSai dans les applications de soins de santé pilotées par l’IA

IPA (IMMUNOPRECISE ANTIBODIES LTD) (la « Société » ou « IPA») (NASDAQ : IPA), InterSystems , un fournisseur créatif de technologies de données qui aide les clients à résoudre leurs défis les plus...

InterSystems and IPA’s Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare Applications

IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), InterSystems, a creative data technology provider dedicated to helping customers solve their most critical scalability...

IPA acquiert l'instrument Carterra LSA® pour améliorer la découverte d'anticorps et renforcer ses développements en matière d'IA

Un débit important de LSA pour faire progresser le développement de médicaments axé sur la diversité et les données d'IPA et pour enrichir LENSai™. IPA (IMMUNOPRECISE ANTIBODIES LTD.) (la «...

IPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI Developments

Significant throughput of LSA to advance IPA’s diversity- and data-driven drug development and to enrich LENSai™. IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an...

IPA présente ses résultats financiers et les récents points forts de son activité pour le troisième trimestre de l’exercice 2024*

IPA annonce un quatrième trimestre consécutif de hausse des revenus IPA (IMMUNOPRECISE ANTIBODIES LTD.) (la « société » ou « IPA ») (NASDAQ : IPA), une entreprise de recherche et de technologie...

IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024*

IPA reports a fourth consecutive quarter of increased revenue. IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an artificial intelligence-driven biotherapeutic...

BioStrand, filiale d'IPA, annonce une avancée majeure dans les sciences du vivant avec son Advanced Foundation AI Model utilisant l'empilement LLM et la technologie HYFT

  Dirk Van Hyfte, MD, PhD, cofondateur et responsable de l'innovation de BioStrand, présentera ces conclusions la semaine prochaine à la conférence HIMSS24 à Orlando, Floride IPA (IMMUNOPRECISE...

IPA’s subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT Technology

 Dirk Van Hyfte MD, PhD, Co-Founder and Head of Innovation of BioStrand, to present findings live next week at the HIMSS24 conference in Orlando, Florida IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the...

L'IPA publiera ses résultats financiers et les faits marquants de sa récente activité pour le troisième trimestre de l'exercice 2024, le 14 mars 2024

L'entreprise organisera une conférence téléphonique sur les résultats par le biais d'une webdiffusion. IPA (IMMUNOPRECISE ANTIBODIES LTD.) (la « société » ou « IPA ») (NASDAQ : IPA), une...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.15-121.251.361.07895191.2042759CS
4-0.14-11.29032258061.241.391.07753611.25023026CS
12-0.65-37.14285714291.752.42991.076123771.76324843CS
26-0.29-20.86330935251.392.60.943520061.72750916CS
52-1.75-61.40350877192.853.390.941998041.78413844CS
156-6.77-86.02287166457.8716.470.942865179.19007105CS
260-20.9-952233.340.942661099.35802952CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
DUOFangDD Network Group Ltd
$ 1.65
(313.74%)
104.68M
FLJFLJ Group Limited
$ 1.54
(220.90%)
57.28M
JFBRJeffs Brands Ltd
$ 0.6276
(102.45%)
37.97M
IPWiPower Inc
$ 2.89
(97.95%)
11.05M
CETXCemtrex Inc
$ 0.4851
(48.58%)
21.23M
BSFCBlue Star Foods Corporation
$ 0.0757
(-45.26%)
60.09M
SINTSiNtx Technologies Inc
$ 0.084602
(-39.57%)
156.35M
FFIEFaraday Future Intelligent Electric Inc
$ 1.0189
(-38.25%)
1.31B
HSCSHeart Test Laboratories Inc
$ 7.00
(-38.11%)
348.9k
AMPGAmplitech Group Inc
$ 1.46
(-32.09%)
613.31k
CRKNCrown Electrokinetics Corporation
$ 0.171
(-28.75%)
1.74B
FFIEFaraday Future Intelligent Electric Inc
$ 1.0189
(-38.25%)
1.31B
GWAVGreenwave Technology Solutions Inc
$ 0.1541
(4.05%)
1.16B
AKANAkanda Corporation
$ 0.1726
(30.26%)
566.49M
PEGYPineapple Energy Inc
$ 0.1053
(-28.85%)
219.25M

IPA Discussion

View Posts
Monksdream Monksdream 1 month ago
IPA under $1
👍️0
Invest-in-America Invest-in-America 2 months ago
IPA: And check-out their final 'CHART' for today, below!!! Perfect for THIS pure-fluff-news baloney "company"!!!

👍️0
Invest-in-America Invest-in-America 2 months ago
IPA: Hey, Capt. TIM!!! (CERO is yet ANOTHER pure FLUFF (Wall Street) Baloney Sandwich Special on a Petri Dish, with a free Test Tube soda, & French Fries on the side!!! How peeps get SUCKERED by such nonsense is beyond me!!)

PS: I will look at CELZ --- thanks!!
👍️0
TIMGZ TIMGZ 2 months ago
CHECK OUT "CELZ" MAY BE "LYT" PART 2.
HOPE YOU SCORE ON "CERO"******IS THIS THE CURE*****THE EPISODE SHALL CONTINUE AS YOU ENUNCIATED*****MAY MORE UPWARD TREND
👍️0
Invest-in-America Invest-in-America 2 months ago
IPA: Toilet flush on a BIBLICAL scale!!! Indeed, more pure FLUFF "news" & otherwise nonsense than in the so-called "HOLY" Western Bible!!! Miracles & Saviors to boot, but we all AGE & DIE anyway!!!!
👍️0
Invest-in-America Invest-in-America 2 months ago
IPA: MONSTER mistake if YOU bought into this debacle of the YEAR, Boss!!!
👍️0
Invest-in-America Invest-in-America 2 months ago
IPA: How come nobody is BRAGGING over here about how much money they LOST on this "Major Breakthrough" in FLUFF news?????
👍️0
TheFinalCD TheFinalCD 2 months ago
heres the problem

February 2024 Clear Street ATM
EDGAR
Registered

Remaining ATM Capacity
$60,000,000
Total ATM Capacity
$60,000,000
ATM Limited by Baby Shelf
No
Remaining Capacity w/o Baby Shelf Restriction
60,000,000
Placement Agent
Clear Street
Agreement Start Date
2024-02-23
Last Update Date
2024-02-23
https://dilutiontracker.com/app/search/IPA?a=dbb88c
👍️0
Awl416 Awl416 2 months ago
IPA’s subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT Technology
👍️0
TheFinalCD TheFinalCD 2 months ago
IPA’s subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT Technology $IPA https://t.co/BoB6s5MFXs— Health Stocks News (@health_stocks) March 7, 2024
https://ih.advfn.com/stock-market/NASDAQ/immunoprecise-antibodies-IPA/stock-news/93349536/form-424b5-prospectus-rule-424b5
👍️0
Monksdream Monksdream 2 months ago
IPA chart
👍️0
Louied91 Louied91 10 months ago
$IPA - "Today, don't miss the Market @RadiusResearch live interview with Dr. Jennifer Bath, IPA CEO. Gain insight into the future of AI in drug discovery, with a post interview Q&A session. Today 4PM EST."

Today, don't miss the Market @RadiusResearch live interview with Dr. Jennifer Bath, IPA CEO. Gain insight into the future of AI in drug discovery, with a post interview Q&A session. Today 4PM EST.
Register now: https://t.co/RxnTkEvDmQ $IPA pic.twitter.com/KOU9KnIrj3— IPA (ImmunoPrecise Antibodies) (@ImmunoPrecise) July 19, 2023
👍️0
Louied91 Louied91 10 months ago
$IPA Subsidiary BioStrand - "Scaling up drug discovery: Exploring the LENS?? approach"

https://blog.biostrand.be/scaling-up-drug-discovery-exploring-the-lensai-approach?utm_content=166736098&utm_medium=social&utm_source=twitter&hss_channel=tw-1195260154318610432
👍️0
Louied91 Louied91 11 months ago
$IPA - "Check out the insightful interview highlighting the market power of IPA, AI innovation in #drugdiscovery and the promising future it holds."

Recently, Dr. Jennifer Bath, CEO of IPA, was interviewed by @SmallcapDisc. Check out the insightful interview highlighting the market power of IPA, AI innovation in #drugdiscovery and the promising future it holds. See interview: https://t.co/6yITze55UT $IPA #AI pic.twitter.com/HK7Kt9fION— IPA (ImmunoPrecise Antibodies) (@ImmunoPrecise) June 28, 2023
👍️0
Louied91 Louied91 11 months ago
$IPA - "Catch up on IPA's cutting-edge AI developments"

Missed Dr. Jennifer Bath, CEO of IPA, in her insightful @Nasdaq interview? 🎥 Don't worry! Catch up on IPA's cutting-edge AI developments by clicking the link below. Stay informed and be a part of the AI revolution! https://t.co/An3o7rq11T $IPA #Nasdaq #AI pic.twitter.com/GPDJDcLMCV— IPA (ImmunoPrecise Antibodies) (@ImmunoPrecise) June 22, 2023
👍️0
Louied91 Louied91 11 months ago
$IPA -"Huge thanks to #Nasdaq for the interview! We appreciate the opportunity to tell the IPA story. Stay tuned for the interview link. "

Huge thanks to #Nasdaq for the interview! We appreciate the opportunity to tell the IPA story. Stay tuned for the interview link. $IPA #BoldInnovation #Innovation #ArtificialIntelligence #AI #DrugDiscovery #Antibodies #TechBio #Biotechnology #Biotherapeutics @Nasdaq pic.twitter.com/gwv23QfP85— IPA (ImmunoPrecise Antibodies) (@ImmunoPrecise) June 14, 2023
👍️0
Louied91 Louied91 11 months ago
$IPA - "CEO, Dr. Jennifer Bath, will be speaking today at the renowned Jefferies Healthcare Conference. Stay tuned for the archive of the live presentation bit.ly/3N0Gb99. Gain insights into the future of biotherapeutics at the intersection of antibody discovery and AI"

IPA CEO, Dr. Jennifer Bath, will be speaking today at the renowned Jefferies Healthcare Conference. Stay tuned for the archive of the live presentation https://t.co/Y0770uPUnN. Gain insights into the future of biotherapeutics at the intersection of antibody discovery and AI.$IPA pic.twitter.com/ErGwFyVpRe— IPA (ImmunoPrecise Antibodies) (@ImmunoPrecise) June 9, 2023
👍️0
Louied91 Louied91 11 months ago
Reminder: $IPA to Present at Jefferies Healthcare Conference 2023

https://www.businesswire.com/news/home/20230517005389/en/

VICTORIA, British Columbia--(BUSINESS WIRE)--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”) an AI-driven biotherapeutic research and technology company today announced that Dr. Jennifer Bath, the company's Chief Executive Officer and President, will present at the Jefferies Healthcare Conference on Friday June 9, 2023, at 11:00 a.m. Eastern time.

The live and archived webcast of the presentation will be accessible from the company’s website at https://ir.ipatherapeutics.com/events-and-presentations/default.aspx. The replay of the webcast will be available for 90 days.
👍️0
The Night Stalker The Night Stalker 12 months ago
nice
👍️0
The Night Stalker The Night Stalker 1 year ago
strong
👍️0
Louied91 Louied91 1 year ago
$IPA - "We just wrapped up a Q&A review for our Investor Report, focusing on #AI, #antibodydiscovery and #biotech! "

We just wrapped up a Q&A review for our Investor Report, focusing on #AI, #antibodydiscovery and #biotech! Explore not only trends and opportunities in these dynamic sectors, but also how IPA is strategically built to advance the future. See insights: https://t.co/qF8hygMWhT$IPA pic.twitter.com/W6FC9GulBQ— IPA (ImmunoPrecise Antibodies) (@ImmunoPrecise) May 18, 2023
👍️0
The Night Stalker The Night Stalker 1 year ago
nice
👍️0
The Night Stalker The Night Stalker 1 year ago
nice
👍️0
The Night Stalker The Night Stalker 1 year ago
right
👍️0
Jess070283 Jess070283 1 year ago
What a flop…. Looking to be just a pump and dumper…
👍️0
The Night Stalker The Night Stalker 1 year ago
big dip
👍️0
Louied91 Louied91 1 year ago
$IPA - "We are excited to share the new BioStrand brand and website. Our strategic focus has been on integrating business units behind the scenes to best serve you, drive innovation in AI technology for genomics, and accelerate the antibody discovery process. "

We are excited to share the new BioStrand brand and website. Our strategic focus has been on integrating business units behind the scenes to best serve you, drive innovation in AI technology for genomics, and accelerate the antibody discovery process. https://t.co/BdNCzfJIse$IPA pic.twitter.com/j7FtVbMpUY— IPA (ImmunoPrecise Antibodies) (@ImmunoPrecise) May 15, 2023
👍️0
The Night Stalker The Night Stalker 1 year ago
nice
👍️0
Jess070283 Jess070283 1 year ago
Rally!!!
👍️0
Louied91 Louied91 1 year ago
$IPA - "Get ready — something exciting is coming next week."

Get ready — something exciting is coming next week.#artificialintelligence #drugdiscovery #innovation #biotech #antibodydiscovery #bioinformatics #HYFTs pic.twitter.com/Aqya71qpO8— IPA (ImmunoPrecise Antibodies) (@ImmunoPrecise) May 12, 2023
👍️0
Singhania Singhania 1 year ago
TheStreetReports: AI Biotech Stocks to Watch 2023: $IPA, $ONTX, $AGEN, $PBIO https://www.marketwatch.com/press-release/thestreetreports-ai-biotech-stocks-to-watch-2023-ipa-ontx-agen-pbio-2023-04-24
👍️0
Louied91 Louied91 2 years ago
IMMUNOPRECISE ANTIBODIES LTD (NASDAQ: $IPA ): CRYSTAL RESEARCH ASSOCIATES ISSUES RESEARCH REPORT

https://frontdesknews.com/2022/05/20/immunoprecise-antibodies-ltd-nasdaqipa-crystal-research-associates-issues-research-report/

Immunoprecise Antibodies Ltd (NASDAQ:IPA) is a full-service contract research organization (CRO) for therapeutic antibody discovery and development. The Company’s technology suite supports the biopharmaceutical industries in their pursuit to discover and develop novel, therapeutic antibodies against various disease targets.

Crystal Research Associates issued an research report on the company. The report states IPA is positioned as a leader in human therapeutic antibody discovery and development, disrupting the conventional multivendor drug discovery model by modernizing the antibody lead candidate selection and downstream development processes.

The Company is addressing one of the greatest challenges in generating new therapies, the lack of access to rigorous and innovative technologies (to serve a $30 billion market and growing).

IPA’s strategy is backed by expanding trends as pharmaceutical/biotechnology companies look to outsource research, improve efficiency, lower development costs, increase turnaround time, and gain access to integrated expertise.
👍️0
Louied91 Louied91 2 years ago
$IPA Selected to Work with Elektrofi on COVID-19 Therapeutic Delivery and Future Pandemic Preparation under SBIR Contract from Defense Health Agency within US Department of Defense

https://www.businesswire.com/news/home/20220314005424/en/IPA-Selected-to-Work-with-Elektrofi-on-COVID-19-Therapeutic-Delivery-and-Future-Pandemic-Preparation-under-SBIR-Contract-from-Defense-Health-Agency-within-US-Department-of-Defense

BOSTON--(BUSINESS WIRE)--Elektrofi (ELEKTROFI, INC) & IPA (IMMUNOPRECISE ANTIBODIES LTD.) (NASDAQ: IPA) (TSXV: IPA) today announced they are entering into a collaboration to explore a high-concentration formulation of IPA’s COVID-19 antibody cocktail, PolyTope® TATX-03. This collaboration aims to generate an IND-enabling data package for the FDA for an alternatively formulated version of TATX-03, named TATX-03E, that could be easily self-administered in a non-healthcare setting. By joining forces, the parties anticipate formulating TATX-03E for stable and rapid distribution to the consumer, a drug product ideally suited to serve unmet needs for rapid deployment, field use, and higher frequency dosing for immunocompromised individuals requiring on-going access to therapies and prophylaxis.

The collaboration between Elektrofi and IPA will be supported by Elektrofi’s contract with the DHA Small Business Innovation Research (SBIR) Program within the Department of Defense (DoD). The companies will begin by conducting formulation feasibility studies followed by IND-enabling, non-clinical studies to establish safety and efficacy with the novel formulation.

“We are impressed by the neutralizing activity demonstrated by ImmunoPrecise’s antibody cocktail against current variants of concern, including Omicron. Nearly all other programs we have looked into partnering with do not demonstrate the ability to neutralize so many variants,” said Daniel Dadon, Director of Scientific Strategy at Elektrofi. “We look forward to working with IPA to develop a product that could potentially improve access to this class of life saving medicines and reduce the burden on healthcare systems.”

“Antibodies have been an essential asset for COVID-19 patients since their introduction earlier in the pandemic,” said Dr. Jennifer Bath, CEO and President of IPA. “We are excited to be working with Elektrofi and applying their formulation technology to these critical therapies, as self-administration could significantly alleviate the burden associated with COVID-19 and future pandemics, as well as other diseases.”
👍️0
Louied91 Louied91 2 years ago
$IPA Updates on Investigational New Drug (IND) Enabling Program for PolyTope® TATX-03

https://finance.yahoo.com/news/ipa-updates-investigational-drug-ind-130100888.html

VICTORIA, British Columbia, March 09, 2022--(BUSINESS WIRE)--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company") (NASDAQ: IPA) (TSXV: IPA) is pleased to report on the latest progress in the development of their PolyTope® TATX-03 antibody cocktail therapy with a proven strong efficacy against all tested SARS-CoV-2 variants-of-concern. The Company reports positive data indicating their recent IND-enabling animal studies do not show any observable acute adverse events, data which supports a highly positive safety profile for TATX-03 as a clinical product. In addition, results from the FDA reviewed and recommended animal study protocols demonstrate that the in vivo pharmacokinetic profiles of the individual antibodies show no aberrations, and each antibody demonstrates a characteristic human IgG1 pharmacokinetic profile.

As a prelude to a formal toxicology study, a maximum tolerated dose and a pharmacokinetic study were completed using injections of up to 12.5 times the anticipated highest dose proposed for the phase 1 clinical trial. The results did not demonstrate any adverse clinical signs, nor any observable effect in behavior, change in appetite, or change in weight, in any of the animals. In addition, monitored vitality indicators, such as body temperature, stayed within their respective physiological ranges, and no post-mortem macroscopic tissue anomalies were observed. In vivo animal serum profiles of each antibody were in full accordance with those expected for human immunoglobulins.

To promote IND approval and a seamless transition to the clinic, the company engages in on-going communications with the FDA regarding the TATX-03 data package. The FDA has advised to enhance the preclinical safety evaluation by examining the build-up of antibody serum concentrations in the laboratory animal model versus humans, recommending a study design adaptation to increase the number of injections and to monitor the elimination of antibodies from the animals. The ongoing final GLP toxicology study is therefore extended by eight weeks with the final data being available mid-June, 2022. These current advancements allow scheduling of Investigational New Drug (IND) filing to the FDA early Q3. Importantly, the timelines for completion of clinical batch production nor the launch of the intended phase 1 clinical trial are not impacted and on schedule as planned.

"The lack of any adverse event, of morbidity, of mortality, of any observable effect in any of the rodents injected with an order more of the highest intended clinical dose of TATX-03, is very encouraging and supports that we have developed a very efficacious and resilient SARS-CoV-2 therapy with an expectedly high safety profile," stated Dr. Ilse Roodink, CSO of IPA.

"Although we are awaiting the outcome of the final GLP toxicology study, all signs indicate that we have designed a safe and effective pharmaceutical," added Dr. Roodink. "We are eager to proceed quickly but carefully to the first clinical trial phase as soon as the TATX-03 drug product is ready for distribution."
👍️0
deri21 deri21 2 years ago
$IPA Marshall Wace LLP Boosts Stock Position in ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) https://zolmax.com/investing/marshall-wace-llp-boosts-stock-position-in-immunoprecise-antibodies-ltd-nasdaqipa/6883519.html
👍️0
vinmantoo vinmantoo 2 years ago
The post was intended sarcasm lol.

Ha, ha, missed that.
👍️0
RNsidersbuying RNsidersbuying 2 years ago
The post was intended sarcasm lol. I'm waiting to hear management's explanation?

👍️0
vinmantoo vinmantoo 2 years ago
Anyone wanna try n take a shot at this..."first generation four antibody cocktail"...WHAT!...does management read this baord???

There is more than room for more than one monoclonal antibody.

Second, that company smells like a scam to me. They show only one figure and that figure purports to show that their Ab cocktail inhibits virus in vitro. However, there is NO scale on the x-axis, which make that lone figure meaningless. Buyer beware.
👍️0
RNsidersbuying RNsidersbuying 2 years ago
This first generation four antibody cocktail against SARS-CoV-2 was rationally designed to sustain efficacy against all SARS-CoV-2 strains and variants with the goal of protecting and treating all individuals.

https://www.immunoprecise.com/immunotherapeutic-polytope-from-ipa-potently-neutralizes-the-sars-cov-2-omicron-variant/

Anyone wanna try n take a shot at this..."first generation four antibody cocktail"...WHAT!...does management read this baord???
👍️0
BottomBounce BottomBounce 3 years ago
The covid19 sector is heating up https://www.benzinga.com/trading-ideas/long-ideas/21/08/22306248/chembio-diagnostics-stock-is-trading-higher-on-fda-emergency-use-nod-for-its-partners-lu
👍️0
BottomBounce BottomBounce 3 years ago
$IPA Covid19 Delta Variant

https://www.businesswire.com/news/home/20210722005490/en/ImmunoPrecises-PolyTope%E2%84%A2-TATX-03-Antibody-Cocktail-Potently-Neutralizes-SARS-CoV-2-Delta-Variant-in-in-vitro-Pseudovirus-Assays
👍️0
Nebuchadnezzar Nebuchadnezzar 3 years ago
$18 to $7--how lovely. FUGLY looking chart

👍️0
Jake L Jake L 3 years ago
IPA - Monday Rundown, Tuesday Expectations

👍️0
Condors rugby Condors rugby 3 years ago

Bought 2k shares today. Think this has potential to double from here in 3 months
👍️0
BottomBounce BottomBounce 3 years ago
https://www.prnewswire.com/news-releases/clinical-trial-affirms-covidth-diagnostic-approach-to-screen-for-t-cell-mediated-immune-response-to-sars-cov-2-is-safe-and-effective-in-humans-301346721.html
👍️0
BottomBounce BottomBounce 3 years ago
Was almost $20 two weeks ago. $IPA I only have 100 shares. I want more.
👍️0
WALL STREET KID WALL STREET KID 3 years ago
Chart looks yummy
👍️0
BottomBounce BottomBounce 3 years ago
Meow
👍️0
BottomBounce BottomBounce 3 years ago
$IPA U.S. reaches COVID-19 milestone of 70% of adults receiving at least one vaccine dose
👍️0
BottomBounce BottomBounce 3 years ago
$IPA ImmunoPrecise Antibodies: The Next Generation of Antibody Discovery

👍️0

Your Recent History

Delayed Upgrade Clock